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Abstract
Loss of muscle mass and function are a well-defined aspect of human aging
from the 3rd decade of life, which result in reduced independence and
increased mortality. The activin family of peptides contains several endocrine
factors (activin A, myostatin, growth and differentiation factor 11 [GDF11])
that may play roles in changes in muscle mass and the aging process, however,
it may be simplistic to consider aging as a result of a single peptides changes.
Thus, we aimed to examine changes in activin family members across a cohort
of healthy individuals of various ages, hypothesizing that these would aid pre-
dictive models of age and functional measures of age. Healthy participants
(n = 88) were recruited and resting metabolic rate, body composition, grip
strength, walking speed, and circulating plasma concentrations of myostatin
(total and free), activin A, follistatin-like binding protein (FLRG), and GDF11
quantified. Simple regressions between circulating factors and chronological
age, grip strength, and walking speed were examined. Multiple stepwise regres-
sions for age, grip strength, and walking speed are also reported. Age nega-
tively correlated with total myostatin (P = 0.032, r2 = 0.053), grip strength
positively with activin A (P = 0.046, r2 = 0.048), whereas walking speed
showed no simple regression relationships. Stepwise regressions suggested a
role of total myostatin and activin A in models of age, whereas GDF11 con-
tributed to the model of grip strength. Here we suggest a role for myostatin,
activin A, and GDF11 in normal human aging that mirrors animal studies to
date. Further interventional studies are required to elicitate the physiological
role of these changes in the normal human aging process, and indeed if offset-
ting these changes can promote successful aging.
Introduction
The aging process is inherent to the human condition,
and involves a loss of muscle mass, muscle function, and
a generalized increase in frailty. Loss of muscle mass and
function occurs at a predictable rate throughout adult-
hood, with evidence of muscle mass loss from 30 years of
age (Kallman et al. 1990; Mitchell et al. 2012; Steiber
2016). At its extreme, sarcopenia is seen in 5–13% of peo-
ple between 60 and 70 years of age, which increased to
50% of those >80 years of age (Metter et al. 2002).
Importantly, Western society continues to show an aging
shift; thus the proportion of older individuals with
reduced muscle function and sarcopenia is predicted to
grow, increasing the load on national healthcare systems
(Harper 2014; Bloom et al. 2015).
Myostatin, also known as growth and differentiation
factor 8 (GDF8; McPherron et al. 1997) is a member of
the transforming growth factor beta (TGFb, activin clade;
Hinck et al. 2016) superfamily. Released mainly by skele-
tal muscle, it acts to negatively regulate muscle mass
through its antianabolic and procatabolic effect directly
on myocytes (Elliott et al. 2012). Myostatin in plasma can
be found in three states, free (unbound), bound to its
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own propeptide, or bound to one of several inhibitory
proteins, with total myostatin thus representing free plus
bound myostatin. Propeptide binding prevents myo-
statins’ atrophic actions (Thies et al. 2001; Jiang et al.
2004), as does binding to the inhibitory peptides such as
follistatin or follistatin-related gene protein (FLRG; Hill
et al. 2002; Amthor et al. 2004; Gilson et al. 2009). Myo-
statins’ role as an endocrine hormone was first suggested
in humans, where a negative correlation between muscle
mass and myostatin peptide concentration in serum was
noted across healthy and cachexic HIV patients (Gonza-
lez-Cadavid et al. 1998). This endocrine role was rein-
forced by Zimmers et al. (2002) who inserted Chinese
hamster ovary (CHO) tumors peripherally in mice, modi-
fied to produce and secrete myostatin. Myostatin secret-
ing tumor mice showed an increase in serum myostatin
concentration and loss of global muscle mass, whereas
CHO nonproducing tumors did not.
The role of myostatin in the human aging process has
not been well-defined in the literature to date. Schulte
and Yarasheski (2001) first demonstrated that free myo-
statin was elevated in serum of older frail woman and
inversely correlated with muscle mass. Furthermore,
increased levels of the free fraction of serum myostatin
have been reported in a cohort of 60- to 75-year-old par-
ticipants relative to a 19- to 35-year-old cohort (Yarash-
eski et al. 2002). Conversely, no significant difference
between serum myostatin was seen between young and
sarcopenic elderly men, nor were any differences between
ages noted in the myostatin binding proteins follistatin
and FLRG (Ratkevicius et al. 2011). These studies have
used between-participant models, examining discrete
cohorts of young/old participants. If there is a change in
myostatin with age, it would be reasonable to hypothesize
that is would be linear and positive, reflecting the changes
in muscle mass and strength that occur during aging.
Other members of the activin subfamily with structural,
and potentially functional, similarity to myostatin exist,
including activin A and growth and differentiation factor
11 (GDF11; Hinck et al. 2016). Activin A has received
much attention with regards to aging, and tends to
increase in later life (Baccarelli et al. 2001; Ebert et al.
2006). Much recent attention has been placed on GDF11
in the aging process. Indeed, the concentration of GDF11
in middle-aged mice is predictive of all-cause mortality
with aging (Zhou et al. 2016). In older mice, GDF11 is
reduced relative to younger, and exogenously supplied
GDF11 restores muscle function toward “younger” values
(Sinha et al. 2014), whereas maintenance of muscular
function with aging in humans is associated with elevated
GDF11 concentrations (Elliott et al. 2017).
A better understanding of the change in these activin
family peptide appears needed, both to begin to gain insight
into their role in aging, and also to develop quantifiable
biomarkers of biological aging. Thus, the aim of this work
was to describe changes in myostatin and closely related
activin-related peptides with age, by recruiting a large
cohort of declared healthy individuals with a cross-sectional
representation of ages. It was hypothesized that activin A
and total myostatin would correlate positively with age,
whereas FLRG and GDF11 would negatively correlate.
Materials and Methods
Ethical approval
Ethical approval was obtained by the Faculty of Science
and Technology Research Ethics sub-Committee, Univer-
sity of Westminster (#VRE1516-0084). All work herein
conforms to the standards set by the Declaration of Hel-
sinki. Written informed consent was obtained from all
participants prior to participation.
Participant descriptors
Declared healthy individuals (range 18–68 years of age,
N = 88, 39 males) were recruited for this study. Partici-
pant sex was self-declared. Inclusion criteria was 18–
80 years of age and clinically stable, with no known car-
diovascular, respiratory, metabolic, or coagulation disor-
ders, no disorders of muscle mass, not a regular smoker
or currently taking any prescription medication (exclud-
ing hormonal contraceptive methods). All participants
were required to have a BMI of 18–30 kg/m2.
Experimental design
Each participant was asked to refrain from structured
exercise for 24 h prior to testing, and fast (nothing but
water) for 12 h prior to testing, therefore presenting for
testing in a fasted, rested state. All participants were
tested between 09:00 and 12:00. The order of testing was
as follows; resting metabolic rate, body composition,
venous blood sample, grip strength, and 6-min walk test
(6MWT). Order was strictly adhered to, and completed
within 90-min per participant.
Resting metabolic rate
Resting metabolic rate (kj/day) was determined by the use
of indirect calorimetry. Briefly, participants lay supine on
a bed in a darkened, thermoneutral environment with a
mask covering the nose and mouth. Continuous gas
exchange was monitored for 40 min (Cortex 3B, Bio-
physik, Germany), with the final 10 min of data presented
here, to ensure participants metabolic rate had plateaued.
2018 | Vol. 6 | Iss. 17 | e13823
Page 2
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Endocrine Myostatin Predicts Age L. V. Barrios-Silva et al.
Immediately on conclusion of the testing, resting heart
rate, and blood pressure were recorded while the partici-
pant was still in a supine position.
Body composition
Height was measured by stadiometer (Seca, Germany) to
0.1 cm, whereas weight was taken on a calibrated set of
scales to 0.1 kg, with the same stadiometer and scales used
for all participants. Body composition was measured by
air volume displacement (Bod-Pod, Life Measurement,
USA. All measures utilized the same equipment. For test-
ing, participants were asked to remove all jewelery and
wear minimal, form-fitting clothing and a swim-cap. Par-
ticipants were asked to breathe normally and avoid exces-
sive movement during testing.
Grip strength
As grip strength is indicated as a marker of muscle func-
tion in aging populations (Cruz-Jentoft et al. 2010),
assessment of grip strength was executed in a standard
manner using a hand-grip dynamometer (TKK501, Takei
Scientific Instruments, Japan) with the participant stand-
ing with the arm straight and palm facing medially. Grip
was measured three times per participant, in the domi-
nant hand, with at least 1-min break between measure-
ments. One hand-grip dynamometer was used for all
measures. The mean of three measures is reported here.
Venous plasma
Venous blood samples were drawn in a standard manner
from a convenient vein of the cubital fossa into 6 mL
lithium heparin tubes. Samples were centrifuged immedi-
ately (10 min, 4470 g, 4°C), with resultant plasma ali-
quoted and frozen (80°C) for further analysis of peptide
concentrations (described below).
Six-minute walk test (6MWT)
A 6MWT was completed in a standard manner (Holland
et al. 2014). Briefly, participants were instructed to walk at a
self-paced velocity, with the verbal instruction to walk as far
as possible, but not to run or jog. Testing was done indoors,
on a 10 m linear track marked in an institutional hallway,
with distance travelled quantified to the nearest meter. All
participants were tested on the same marked track.
ELISA
Aliquots of plasma were analyzed for total myostatin, free
myostatin (both DGDF80, R&D Systems, UK), FLRG
(DFLRG0, R&D Systems, UK), activin A (DAC00B, R&D
Systems, UK), FLRG (DFLRG0, R&D Systems, UK), and
GDF11 (DY1958, R&D Systems, UK) were analyzed
according to manufactures instructions. Total myostatin
was measured by the acidification release method. Briefly,
100 lL plasma was treated with 50 lL 1N HCl, vortexed
and incubated at room temperature for 10 min then neu-
tralized with 50 lL 1.2 N NaOH and further diluted in
200 lL manufacturer provided diluent for a final dilution
of 1:4, similar to previously validated methods (Lakshman
et al. 2009). Plasma samples for free myostatin were
diluted 1:4 in identical diluent, without acidification or
neutralized treatment. All samples and standard were ana-
lyzed in triplicate. Of the 88 participants, 56 GDF11
results were either below limit of detection of our assay
(31.3 pg/mL) or otherwise undetectable, and are thus not
reported here.
As GDF11 has been previously reported to have a high
structural similarity to myostatin/GDF8 (Poggioli et al.
2016), we also directly compared the GDF11 ELISA used
here against recombinant myostatin in a physiological (0–
2000 pg/mL) and supra-physiological (20,000 pg/mL)
range, with no cross reactivity reported (Fig. 1).
Statistics
All figures were generated in GraphPad Prism (Version 5,
GraphPad), and statistical analysis was performed using
SPSS (version 23, IBM). Pearson’s correlation was used
out to examine possible associations between collected
endocrine variables and a) age (years), b) grip strength
(kg) and c) 6-min walk distance (m). A P-value of less
than 0.05 was considered significant throughout.
Figure 1. GDF11 ELISA antibody does not detect recombinant
myostatin in a physiological or supra-physiological range. Concentration
of GDF11 (0–2000 pg/mL) and myostatin (0–20,000 pg/mL) as a
function of absorbance (450–570 nm). Samples run in triplicate and
reported here as mean with standard error. Solid line indicates linear
regression for GDF11, dashed line for myostatin.
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Automatic linear modeling was used for forward stepwise
regression with an endpoint when Akaike information cri-
terion, conservative (AICC) was minimized. Predictor
importance of generated models were calculated as the
residual sum of squares with the variable removed from
the model, normalized to a sum of 1 to indicate relative
value of individual factors to the total model. Outlines
were removed if > 3 SD from mean, as recommended by
Yang (2013).
Results
Activin factors predict age and grip strength
To examine the relationship between myostatin peptide
family members and chronological age, the concentration
of each peptide was expressed as a function of age (years).
Total myostatin showed a negative linear correlation with
age (P = 0.032, r2 = 0.053, Fig. 2A), whereas free myo-
statin did not (P = 0.123, r2 = 0.031, Fig. 2B). FLRG did
not show a correlation with age (P = 0.122, r2 = 0.028,
Fig. 2C), nor did GDF11 (P = 0.300, r2 = 0.036, Fig. 2E)
or activin A (P = 0.087, r2 = 0.040, Fig. 2E, Table 1).
With regards to functional measures of aging, activin A
shows a positive linear correlation with grip strength
(P = 0.046, r2 = 0.048, Fig. 2J). No other endocrine fac-
tors correlated with grip strength, and no endocrine fac-
tors correlated with 6-min walk distance covered
(Fig. 2K–O, Tables 2 and 3).
Activin peptides aid prediction of age and
frailty
While only total myostatin significantly correlated with
age, albeit weakly with a small coefficient of determina-
tion, we next wished to examine the contribution of tra-
ditionally relevant makers of aging (body composition
and cardiovascular health) and the activin family of
peptides to chronological aging and aging-associated
markers of frailty, using a linear stepwise regression
model.
Systolic blood pressure was the primary predictor of
chronological age from the variables we collected here
(r2 = 0.129, predictor importance = 0.365, P < 0.001),
with a moderately strong model of age being formed by
systolic blood pressure, total myostatin, resting metabolic
rate, resting heart rate, activin A, fat mass, and 6-min
walk distance (adjusted r2 = 0.336, predictor impor-
tance = 1.0, P < 0.001; Table 4) with no other variables
further adding to this model (Fig. 3A). Grip strength, as
one of the two measures of function recorded, was best
predicted by fat-free mass (r2 = 0.607, predictor impor-
tance = 0.560, P < 0.001), and made a very strong model
with the addition of sex, 6-min walk distance and GDF11
(adjusted r2 = 0.718, predictor importance = 1, P =
0.009, Table 5), with no other variables adding to this
model (Fig. 3B). Finally, 6-min walk distance was best
predicted by grip strength (r2 = 0.275, predictor impor-
tance = 0.346, P = 0.008). A weak model of prediction of
6-min walk distance (m) was formed by grip strength,
diastolic blood pressure, age, and BMI (adjusted
r2 = 0.150, predictor importance = 1, P < 0.001) with no
other variables adding to the strength of this model
(Fig. 3C, Table 6).
Discussion
In line with our hypothesis, here we demonstrate that
both total myostatin and activin A appear to indepen-
dently predict age, along with traditionally recognized
aging factors such as blood pressure and muscle mass.
However, counter to our hypothesis, the total myostatin/
age relationship was negative, not positive. This involve-
ment of the activin group of peptides in the aging process
is reinforced by our finding that total myostatin, activin
and GDF11 fit into predictive regression models of both
age and a functional change with age (grip strength), but
possibly in a manner that we do not yet physiologically
understand. Importantly, these factors fix complex, but
not simple regressions, suggesting integrated models
should be considered.
Myostatin
Myostatin’s central roles in the regulation of muscle mass
have been previously described (Elliott et al. 2012). The
role of aging in myostatin concentration has received
prior attention, with mixed results. Prior cohort based
approaches (younger compared to older) have previously
been reported, with one suggesting an increase in plasma
myostatin in older woman relative to younger (Yarasheski
et al. 2002), a similarly designed examination showed no
difference in plasma myostatin between a young and
older cohort (Ratkevicius et al. 2011), and the third sug-
gesting serum myostatin was decreased in older individu-
als relative to younger (Lakshman et al. 2009). To better
examine this disparity, we selected a cross-sectional
approach. While we show a negative correlation between
age and total myostatin, our results most closely mimic
those of Ratkevicius et al. (2011) and Lakshman et al.
(2009). Indeed, had we used a young/older cohort
approach in our study, grouping our participants into
younger (under 35 years of age, n = 44) and older (over
50 years of age, n = 17) our results would be in agree-
ment with Ratkevicius et al. (2011), showing no differ-
ence between myostatin concentration between groups
2018 | Vol. 6 | Iss. 17 | e13823
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(young = 2631.4 (188.7), older = 2323.5 (143.2) pg/mL,
unpaired t-test, P = 0.351 [data not shown]).
While the role of total myostatin in the aging process
remains unclear from this report, the well-recognized role
of myostatin in muscle size regulation (Elliott et al. 2012)
makes it tempting to speculate that myostatin is playing a
role in the aging process. Alternatively, it is equally plau-
sible that the muscle mass decreases seen with increasing
age are resulting in a reduced systemic concentration of
total myostatin. While causation is not shown by this
work, this correlative relationship is of interest to note
and requires further investigation.
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Figure 2. Peptide concentration (pg/mL) as a function of age (years), grip strength (kg) and 6-min walk performance (m). (A–E) Age (years),
(F–J) Grip strength, (K–O) 6-min walk distance covered (m), as a function of concentration of total myostatin (top row), free myostatin (second
row), FLRG (middle row), GDF11 (forth row), and activin A (bottom row). All concentrations in pg/mL.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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While pharmacological inhibition of myostatin is noted
to result in increased muscle mass in mice (Whittemore
et al. 2003), causative data in humans does not yet exist.
Observational human data suggest that the K153R myo-
statin SNP variant associates with grip strength in an
older female cohort (Seibert et al. 2001), and also associ-
ated with reaching 100 years of age (Garatachea et al.
2013). These data suggest that myostatin may still form a
useful target for counteracting the loss of muscle func-
tion, and the subsequent health impact, with age.
GDF11
Much recent attention has been placed on the role of
GDF11 in aging and frailty. The concentration of circulat-
ing GDF11 in middle-aged mice predicts life span (Zhou
Table 1. Activin family members (pg/mL) by age (years). Data are given as mean (standard error).
Age (years) Total myostatin Free myostatin FLRG Activin A GDF11
18–29 2758.5 (270.6) 1386.4 (149.2) 4563.8 (202.2) 261.2 (19.5) 774.8 (243.6)
30–39 2450.5 (190.3) 1508.8 (146.3) 4976.4 (269.7) 352.7 (33.7) 1176.7 (289.4)
40–49 2137.5 (159.1) 1165.7 (104.6) 4883.0 (261.5) 298.4 (32.1) 963.8 (155.8)
50–59 2496.1 (198.5) 1332.2 (165.7) 4929.4 (231.3) 351.3 (32.8) 177.4 (80.8)
60< 2035.9 (171.7) 1240.3 (143.4) 5720.1 (303.8) 351.5 (40.1) 52.5 (—)1
1n = 1 participant over 60 years of age participant had GDF11 concentrations above the limits of detection, thus no error is reported on this
value.
Table 2. Activin family members (pg/mL) by grip strength (kg), binned by quartiles.
Grip strength (quartiles) Total myostatin Free myostatin FLRG Activin A GDF11
<24 2281.8 (194.4) 1444.7 (130.5) 5138.3 (525.3) 298.7 (23.6) 320.3 (33.6)
25–49 1849.6 (147.9) 985.0 (71.9) 4707.2 (232.9) 265.6 (22.5) 280.8 (18.2)
50–74 2940.8 (258.9) 1350.2 (131.5) 4713.8 (207.4) 308.3 (29.2) 400.0 (96.2)
75< 2741.1 (211.3) 1590.0 (169.8) 4837.6 (275.5) 372.1 (36.2) 417.7 (92.4)
Data are given as mean (SE).
Table 3. Activin family members (pg/mL) by 6 min walk distance (m), binned by quartiles.
Grip strength (quartiles) Total myostatin Free myostatin FLRG Activin A GDF11
<24 2288.5 (154.0) 1380.3 (98.9) 5236.8 (259.8) 287.5 (20.0) 356.8 (84.8)
25–49 2160.9 (178.2) 1291.9 (160.9) 4876.0 (229.5) 296.0 (23.7) 325.5 (44.5)
50–74 2666.2 (218.5) 1296.2 (101.5) 4565.7 (208.5) 335.0 (35.7) 325.4 (27.0)
75< 2738.0 (319.8) 1420.4 (184.6) 4712.9 (259.3) 331.8 (36.3) 428.1 (106.2)
Data are given as mean (SE).
Table 4. Forward stepwise regression for age (years).
Model Variable AICC Predictor importance
1 Systolic blood pressure (mmHg) 461.2 0.365
2 . . ... + Total myostatin (pg/mL) 454.2 0.170
3 . . ... + Resting metabolic rate (kj/day) 450.4 0.120
4 . . ... + Resting heart rate (beats/min) 448.3 0.118
5 . . ... + Activin A (pg/mL) 446.2 0.096
6 . . .. + Fat mass (kg) 444.2 0.071
7 . . .. + 6 min walk (m) 442.5 0.060
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et al. 2016), whereas the provision of exogenous GDF11
in older mice restores age-related decreases in grip
strength and endurance performance in mice (Sinha et al.
2014). It has also been reported that that GDF11 and
myostatin had similar, atrophic effects on myocytes
in vitro and muscle cells in vivo, acting via the same
receptor and SMAD-dependent pathway (Egerman et al.
2015). Indeed, GDF11 has a highly similar sequence
homology with myostatin (Hinck et al. 2016). It should
be noted that myostatin in vivo circulates at much higher
concentrations than GDF11 (we report here myostatin in
the ng/mL range, while GDF111 is in the pg/mL range),
potentially explaining this contradictory result. Indeed,
Poggioli et al. (2016) conducted a careful analysis of anti-
body specificity with GDF11, and reported decreased
GDF11 across multiple mammalian species with aging, in
line with our results reported here. Finally, we do note
that our assay shows specificity for GDF11 (Fig. 1), and
does not interact with myostatin, a caution that others
have previously raised (Poggioli et al. 2016).
We here further the results of others in small mammal
models (Loffredo et al. 2013; Sinha et al. 2014; Poggioli
et al. 2016), but for the first time in an aging human
population. If the role of GDF11 in the human is main-
tained from these small animal models, then future work
should target this aging-associated decrease in GDF11
expression. An exciting hypothesis would be that restora-
tion of GDF11 to “younger” levels would result in a
restoration in muscle function and offset frailty, as has
been suggested in mice (Sinha et al. 2014). Indeed, as we
recently reported, successfully aging older individuals
show higher expression of GDF11 than body mass-
matched control older individuals (Elliott et al. 2017),
utilizing the method of measuring GDF11 that we report
here. Besides this report, limited work has examined
GDF11 and human aging. Further work targeting alter-
ations in GDF11 in aging humans, either by environmen-
tal or pharmacological approaches, and subsequent
changes in muscle function, is clearly needed.
Activin A
Of the members of the activin clade of endocrine signal-
ing peptides examined here, the role of activin A in aging
is best understood. Indeed, Baccarelli et al. (2001)
reported activin A did not change in healthy males and
postmenopausal women before 60–70 years of age, using
a similar cross-sectional design as that used here. These
results were mirrored by Ebert et al. (2006). A smaller
Figure 3. Prediction of aging factors as a function of actual factor.
(A) Predicted age (years) as a function of age (years). (B) Predicted
grip (kg) as a function of grip (kg). (C) Predicted 6MWT distance
(m) as a function of 6MWT distance (m).
Table 5. Forward stepwise regression for grip strength (kg).
Model Variable AICC Predictor importance
1 Fat free mass (kg) 369.7 0.560
2 . . .. + Sex 349.3 0.336
3 . . .. + 6 min walk (m) 343.0 0.080
4 . . .. + GDF11 (pg/mL) 342.9 0.024
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longitudinal cohort suggested that activin A was increased
over 10 years in males, but not females (Loria et al.
1998). Furthermore, serum from older women (43–47)
show increased activin A relative to younger (19–38)
women (Santoro et al. 1999). Our results mirror those
previously reported (Baccarelli et al. 2001; Ebert et al.
2006) with no change in activin A in a healthy population
of younger-to-older individuals.
FLRG
FLRG is an inhibitor of myostatin, yet its effects on
aging has received considerably less attention. We chose
to examine it here to investigate the hypothesis that
aging-associated frailty may involve myostatin via a
decrease in FLRG-dependent inhibition. The results we
present here suggest that FLRG is not involved in the
aging process, with no alteration in chronological age
or either marker of function (grip strength and walking
speed), nor any involvement in our regression models.
These findings are supported by Ratkevicius et al.
(2011) who showed no change in FLRG, nor other
myostatin inhibitors (follistatin or growth/differentiation
factor-associated serum protein-1 [GASP-1]), matching
our results here.
Conclusions
Here we report that the concentration of total myo-
statin tends to decrease as a function of age in other-
wise healthy individuals, in addition total myostatin,
activin A and GDF11 are predictive of chronological
age and grip strength. As an inhibitor of myostatin,
FLRG does not appear involved in the normal aging
process. The decrease in total myostatin appears to be
involved in the aging process, as it is the only factor
that fits into both our simple and complex regression
models of aging. The GDF11-grip strength findings are
exciting, as it mimics data seen previously in aging
mice. We thus suggest that future research into modifi-
cation of GDF11 and myostatin levels in the aging
human are needed.
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